Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec 14:9:88.
doi: 10.1186/1475-2840-9-88.

log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males

Michel P Hermans  1 , Sylvie A Ahn, Michel F Rousseau
Affiliations

log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males

Michel P Hermans et al. Cardiovasc Diabetol. .

Abstract

Background: T2DM is associated with atherogenic dyslipidemia (AD), defined as decreased HDL-C plus raised triglycerides (TG). AD confers increased risk for CAD, even when LDL-C is at target. AD is rarely assessed due to lack of screening methods consensus.

Aim: To establish the prevalence and severity of AD from log(TG)/HDL-C in T2DM males, and to determine how it relates to cardiometabolic phenotype, glucose homeostasis, micro- and macrovascular complications, and 10-year UKPDS CV risk.

Methods: 585 T2DM males divided according to quintiles (Q) of log(TG)/HDL-C. AD prevalence defined as HDL-C <40 mg x dL(-1) plus TG ≥150 mg x dL(-1). β-cell function assessed with HOMA.

Results: Mean HDL-C and TG were 44 (13) and 204 (155) mg x dL(-1). AD prevalence was 35%. AD correlated with lower β-cell function, with accelerated loss of insulin secretion, and with poorer HbA1c levels. AD was related to a high prevalence of CAD, and also to 10-year absolute CAD risk.

Conclusions: log(TG)/HDL-C is a simple means to estimate AD and the residual CV risk it confers in T2DM. AD closely associates with major cardiometabolic and glucose homeostasis determinants and poorer metabolic control. The ratio also relates to macroangiopathy prevalence and ranks future CAD risk, and is well-suited to capture non-LDL-related macrovascular residual risk and major glycemic determinants.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Contribution of individual components of the metabolic syndrome (MetS) phenotype to the MetS cumulative score in 585 male patients with T2DM, divided into quintiles (n = 117; QI to QV) based on log(TG)/HDL-C ranking distribution. HBP: high blood pressure; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides.
Figure 2
Figure 2
UKPDS Risk Engine 10-year absolute predicted risk of developing non-fatal or fatal coronary artery disease (CAD; grey bars) or fatal CAD (solid bars) in 331 T2DM males according to quintiles of log(TG)/HDL-C ranking distribution. Within each quintile, data were obtained from subsets of patients in primary cardiovascular prevention: QI: n = 83; QII: n = 59; QIII: n = 65; QIV: n = 65; and QV: n = 59. HDL-C: high-density lipoprotein cholesterol; TG: triglycerides. Significance of differences between quintiles: P < 0.0001 (CAD) and P = 0.0004 (fatal CAD).
See this image and copyright information in PMC

References

    1. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 2009;32:S13–61. doi: 10.2337/dc09-S013. - DOI - PMC - PubMed
    1. Davignon J, Cohn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis. 1996;124:S57–64. doi: 10.1016/0021-9150(96)05858-3. - DOI - PubMed
    1. Brites FD, Bonavita CD, De Geitere C, Cloës M, Delfly B, Yael MJ, Fruchart J, Wikinski RW, Castro GR. Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis. 2000;152:181–92. doi: 10.1016/S0021-9150(99)00452-9. - DOI - PubMed
    1. da Luz PL, Favarato D, Faria-Neto JR Jr, Lemos P, Chagas AC. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo) 2008;63:427–32. - PMC - PubMed
    1. Fruchart J-C, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche J-M, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. for the Residual Risk Reduction Initiative. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102:S1–34. doi: 10.1016/j.amjcard.2008.10.002. - DOI - PubMed

MeSH terms